Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. (Q34743609)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. |
scientific article |
Statements
Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT (English)
Zariana Nikolova
George D Demetri
Charles D Blanke
Burton Eisenberg
Jonathan A Fletcher
Christopher L Corless
Christopher D M Fletcher
Peter J Roberts
Daniela Heinz
Elisabeth Wehre
1 February 2008